{"product_id":"treating-male-partners-of-women-with-bacterial-vaginosis-a-promising-new-dual-therapy-approach-explained","title":"Treating Male Partners of Women with Bacterial Vaginosis: A Promising New Dual-Therapy Approach Explained","description":"\u003cp\u003eBacterial vaginosis (BV) is one of the most common vaginal conditions affecting women worldwide, yet its treatment remains frustratingly ineffective — over half of all women experience a recurrence within 6 to 12 months of standard therapy. This pilot study from Melbourne, Australia, tested a bold new idea: treating the male sexual partners of women with BV using both oral antibiotics and topical antibiotic cream, alongside treating the woman herself. Twenty-two couples participated in the study, and the results showed that this dual-partner treatment approach was highly acceptable and well-tolerated, with most participants taking over 90% of their prescribed medication. The treatment produced immediate and sustained beneficial changes in the vaginal bacteria of women and immediate reductions in BV-associated bacteria on penile skin, supporting the need for larger clinical trials to determine whether this strategy can finally reduce the unacceptably high recurrence rate of BV.\u003c\/p\u003e\n\n\u003ch1\u003eTreating Male Partners of Women with Bacterial Vaginosis: A Promising New Dual-Therapy Approach Explained\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#what-is-bv\"\u003eWhat Is Bacterial Vaginosis?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#why-this-matters\"\u003eWhy This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#study-design\"\u003eStudy Design and Participants\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#treatment\"\u003eThe Treatment Approach\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#how-conducted\"\u003eHow the Research Was Conducted\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recruitment\"\u003eKey Findings: Who Participated in the Study\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#acceptability\"\u003eKey Findings: Was the Treatment Acceptable and Well-Tolerated?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#microbiota\"\u003eKey Findings: Changes in the Genital Microbiota of Couples\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#clinical-implications\"\u003eClinical Implications: What This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eStudy Limitations: What This Research Could Not Prove\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eBV recurs in over 50% of women within 6–12 months of standard treatment.\u003c\/li\u003e\n\u003cli\u003eMale partners can carry BV-associated bacteria on penile skin and in the urethra.\u003c\/li\u003e\n\u003cli\u003eIn a 22-couple pilot, combined oral and topical antibiotic treatment was acceptable and well-tolerated.\u003c\/li\u003e\n\u003cli\u003eThe treatment lowered BV-associated bacteria in both vaginal and penile skin samples at day 8.\u003c\/li\u003e\n\u003cli\u003eLarger trials are needed to determine if partner treatment reduces BV recurrence long-term.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"what-is-bv\"\u003eWhat Is Bacterial Vaginosis?\u003c\/h2\u003e\n\n\u003cp\u003eBacterial vaginosis (BV) is a common condition that occurs when the normal balance of bacteria in the vagina is disrupted. In a healthy vagina, \u003cem\u003eLactobacillus\u003c\/em\u003e species (beneficial bacteria that produce hydrogen peroxide and lactic acid) dominate and keep the environment mildly acidic, which helps ward off harmful microorganisms. In BV, however, there is a dramatic decrease in \u003cem\u003eLactobacillus\u003c\/em\u003e and an increase in the number and diversity of anaerobic bacteria — organisms that thrive without oxygen — which are collectively known as BV-associated bacteria.\u003c\/p\u003e\n\n\u003cp\u003eThese BV-associated bacteria include \u003cem\u003eGardnerella vaginalis\u003c\/em\u003e, \u003cem\u003ePrevotella\u003c\/em\u003e species, \u003cem\u003eSneathia\u003c\/em\u003e species, \u003cem\u003eAtopobium vaginae\u003c\/em\u003e, \u003cem\u003eMegasphaera\u003c\/em\u003e species, and Clostridia-like bacteria (referred to as BVAB-1, BVAB-2, and BVAB-3), among others.\u003c\/p\u003e\n\n\u003cp\u003eBV is not merely a nuisance. It is associated with serious health consequences, including adverse pregnancy outcomes, an increased risk of pelvic inflammatory disease (an infection of the female reproductive organs), and increased susceptibility to HIV and other sexually transmitted infections (STIs).\u003c\/p\u003e\n\n\u003ch2 id=\"why-this-matters\"\u003eWhy This Research Matters\u003c\/h2\u003e\n\n\u003cp\u003eCurrent recommended treatments for BV — typically oral or vaginal antibiotics such as metronidazole or clindamycin — are associated with an unacceptably high recurrence rate, with more than 50% of women experiencing a repeat episode within 6 to 12 months. This means that for many women, BV becomes a chronic, recurring problem that significantly affects their quality of life.\u003c\/p\u003e\n\n\u003cp\u003eWhy does BV keep coming back? Researchers have proposed several possible mechanisms:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRe-infection from a sexual partner:\u003c\/strong\u003e The male partner may harbour BV-associated bacteria and pass them back to the woman after her treatment is complete.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAn endogenous (internal) source:\u003c\/strong\u003e The bacteria may persist in the woman's own body, surviving treatment and multiplying again later.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFailure to recolonize with protective \u003cem\u003eLactobacillus\u003c\/em\u003e:\u003c\/strong\u003e After antibiotics eliminate the harmful bacteria, the beneficial ones may fail to return, leaving the vagina vulnerable to reinfection.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThere is strong observational evidence that sexual activity plays a key role in both the acquisition and recurrence of BV. A meta-analysis (a statistical analysis combining the results of multiple studies) found associations between the lack of condom use and exposure to new or multiple sexual partners with BV. Additionally, two cohort studies of women who have sex with women reported a significant association between acquiring BV and reporting a new sexual partner or a partner who had BV.\u003c\/p\u003e\n\n\u003cp\u003eMicrobiological data also support the sexual transmission theory. The coronal sulcus (the groove behind the head of the penis) and the distal urethra (the lower portion of the urethra) can harbour BV-associated bacteria. Male partners of women with BV have been shown to have an increased abundance of BV-associated bacteria in their penile skin and urethral microbiota compared to male partners of women without BV.\u003c\/p\u003e\n\n\u003cp\u003eDespite this strong evidence, previous randomised controlled trials (RCTs) of male partner treatment have failed to reduce BV recurrence. A recent Cochrane review (a highly respected systematic review of medical research) rated the quality of this evidence as low to very low. The researchers of this pilot study believed that the discrepancy between the epidemiological evidence and past clinical trial results is likely due to methodological limitations. Importantly, none of the earlier trials evaluated \u003cem\u003etopical\u003c\/em\u003e antibiotic therapy for males.\u003c\/p\u003e\n\n\u003cp\u003eThe researchers hypothesised that while bacteria living in the urethra are more likely to be effectively targeted by oral antibiotics, bacteria colonising the skin of the coronal sulcus are more likely to be cleared by topical antibiotics applied directly to the skin. Therefore, they reasoned, a combination of both oral and topical antimicrobial therapy may be required to effectively clear BV-associated bacteria from both the coronal sulcus and the distal urethra.\u003c\/p\u003e\n\n\u003cp\u003eTopical therapy is also likely to be particularly important in uncircumcised males, who have been found to carry a high abundance of sub-preputial (under the foreskin) BV-associated bacteria. Male circumcision has been shown to reduce the detection of BV-associated bacteria in men and to reduce the risk of BV acquisition in their female partners, providing further evidence that carrying BV-associated bacteria on penile skin plays an important role in the development and recurrence of BV.\u003c\/p\u003e\n\n\u003ch2 id=\"study-design\"\u003eStudy Design and Participants\u003c\/h2\u003e\n\n\u003cp\u003eThis pilot study was conducted at the Melbourne Sexual Health Centre (MSHC) in Melbourne, Australia, with recruitment taking place from August 2015 to February 2016. The sample size was determined by the funds available for this pilot project (a \"Near Miss Grant\" awarded to Associate Professor Catriona Bradshaw by the Central Clinical School, Monash University).\u003c\/p\u003e\n\n\u003cp\u003eWomen presenting to the clinic with vaginal symptoms were routinely tested for BV using two standard diagnostic methods: the Nugent score (a microscopic scoring system that grades vaginal bacteria from 0 to 10) and Amsel criteria (a set of four clinical signs; at least three must be present for a BV diagnosis). For this study, BV was defined as a Nugent score of 4 to 10 combined with at least 3 Amsel criteria. Women diagnosed with symptomatic BV who had a regular male partner and expressed interest in the study were referred to a research nurse for eligibility screening.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eWomen were eligible\u003c\/strong\u003e if they were between 18 and 55 years old, were being treated for symptomatic BV, and had a single regular male sexual partner who was willing to enrol in the trial. For the purpose of this study, a \"regular partner\" was defined as someone considered by the woman to be her boyfriend or partner.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eWomen were ineligible\u003c\/strong\u003e if they were HIV positive, pregnant or breastfeeding, diagnosed with current pelvic inflammatory disease, allergic to the study medications, or had other concurrent sexual partners.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eMen were ineligible\u003c\/strong\u003e if they were HIV positive, allergic to metronidazole and\/or clindamycin, or had other concurrent sexual partners.\u003c\/p\u003e\n\n\u003ch2 id=\"treatment\"\u003eThe Treatment Approach\u003c\/h2\u003e\n\n\u003cp\u003eEach couple received a coordinated, dual-partner treatment plan:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWomen\u003c\/strong\u003e received oral metronidazole 400 mg twice daily for 7 days. If metronidazole was contraindicated or declined, they received 2% vaginal clindamycin cream (one applicator vaginally) for 7 consecutive nights.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMale partners\u003c\/strong\u003e received oral metronidazole 400 mg twice daily \u003cem\u003eand\u003c\/em\u003e were instructed to apply a 2 cm diameter volume of 2% clindamycin cream topically to the head of the penis and upper shaft (under the foreskin if uncircumcised) twice daily for 7 days.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eWhere possible, the male partner started treatment on the same day as his female partner; however, treatment could be commenced within one week of the woman starting therapy. Participants received a voucher as reimbursement for their time, valued up to a maximum of AUD $50, depending on the number of study visits completed.\u003c\/p\u003e\n\n\u003cp\u003eDuring the treatment period (days 0 to 7), couples were asked to either abstain from penile-vaginal sex or to have protected (condom-protected) sex.\u003c\/p\u003e\n\n\u003ch2 id=\"how-conducted\"\u003eHow the Research Was Conducted\u003c\/h2\u003e\n\n\u003cp\u003eBefore starting treatment, women completed a questionnaire recording demographic, behavioural, clinical, and contraceptive information. They also provided two self-collected high-vaginal swabs (using Copan flocked swabs) for Nugent scoring and microbiota analysis. Men completed a questionnaire recording demographic and behavioural information, and provided a self-collected penile swab and a urine swab for microbiota analysis.\u003c\/p\u003e\n\n\u003cp\u003eThe penile swab was obtained by rubbing a Copan flocked swab moistened with sterile water around the coronal sulcus and over the glans (head) of the penis. Men were instructed to rub the swab firmly twice around the coronal sulcus before using the same swab to rub the glans. Uncircumcised men were instructed to pull back their foreskin before collecting the swab. For the urine swab, men urinated the first 20 mL of urine into a urine pot and dipped a Copan flocked swab into the collected urine.\u003c\/p\u003e\n\n\u003cp\u003eParticipants then returned weekly questionnaires and self-collected genital specimens for four weeks following completion of treatment — specifically at day 8, day 14, day 21, and day 28. At each time point, women provided a vaginal swab and a vaginal smear for Nugent scoring; men provided a penile swab and a urine swab. Questionnaires and specimens were returned by mail.\u003c\/p\u003e\n\n\u003ch3\u003eLaboratory and Statistical Methods\u003c\/h3\u003e\n\n\u003cp\u003eIn the laboratory, the composition of the genital microbiota (the community of bacteria living in the genital tract) was determined using 16S rRNA gene sequencing, a sophisticated molecular technique that identifies and quantifies the bacteria present in a sample by sequencing a specific gene common to all bacteria. Bacterial diversity was measured using the Shannon Diversity Index, and changes in microbial community composition were assessed using the Bray-Curtis index — a statistical measure that compares how similar or different two bacterial communities are. Bray-Curtis scores range from zero (indicating substantial change) to one (indicating minimal change).\u003c\/p\u003e\n\n\u003cp\u003eAll swabs were rotated in 1 ml of RNAlater (a solution that preserves genetic material) and stored at -80°C for later analysis. DNA was extracted using an automated MagNAPure96 system. A quantitative β globin assay was performed to assess whether each specimen was adequate, and a quantitative 16S PCR was performed to measure the total bacterial load. Twenty negative control samples were included to help identify reagent contaminants. Sequencing was performed on the Illumina MiSeq platform.\u003c\/p\u003e\n\n\u003cp\u003eA total of 6,674,016 sequencing reads remained after post-processing and contaminant removal. Specimens were rarefied to an even sampling depth of 1,100 reads prior to analysis. Two cutaneous penile specimens and thirteen urine specimens did not produce an adequate number of reads and were excluded from further analysis. As a result, there were insufficient urine specimens to enable paired comparisons before and after treatment, so the urethral microbiota analysis could not be completed.\u003c\/p\u003e\n\n\u003cp\u003eStatistical analyses included paired t-tests for bacterial load comparisons, Wilcoxon signed-rank tests for changes in diversity and abundance, and McNemar's chi-squared test for changes in the prevalence of specific bacteria. A p-value of less than 0.05 was deemed statistically significant, which means there is less than a 5% probability that the finding occurred by chance. For multiple comparisons, a false discovery rate adjustment was performed using the Benjamini-Hochberg procedure, with a q-value of less than 0.05 considered significant.\u003c\/p\u003e\n\n\u003cp\u003eAll women with BV also had their vaginal smears undergo blinded Nugent scoring by an experienced microscopist, so that researchers could record whether or not BV recurred within the 28-day follow-up period — although the study was not specifically designed (powered) to measure BV recurrence as an outcome.\u003c\/p\u003e\n\n\u003ch2 id=\"recruitment\"\u003eKey Findings: Who Participated in the Study\u003c\/h2\u003e\n\n\u003cp\u003eOf the 41 women referred to the research nurse, 14 declined to participate and 3 were deemed ineligible. Twenty-four women were invited to attend a screening visit, and of these, 22 male partners (92%) were co-enrolled, resulting in 22 couples in total. Two male partners declined participation after the woman had been screened. Male partners were recruited either by phone with an electronic medical record consultation (n = 14, 64%) or by on-site clinic consultation (n = 8).\u003c\/p\u003e\n\n\u003cp\u003eTwenty-one couples (95%) received the study medication and provided baseline data, as one couple withdrew before completing any study procedures due to the end of their relationship. After providing baseline data, four couples were lost to follow-up (19%) and one withdrew due to a family emergency. This left 16 couples (76%) who completed all study procedures and provided adherence, tolerability, and follow-up data.\u003c\/p\u003e\n\n\u003cp\u003eThe baseline characteristics of the 21 treated couples were as follows:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMean age:\u003c\/strong\u003e 28.6 years (standard deviation 6.4 years) for women and 33.1 years (standard deviation 9.1 years) for men\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCountry of birth:\u003c\/strong\u003e Approximately half of participants were Australian-born (52% of women and 55% of men)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSmoking:\u003c\/strong\u003e Reported by 8 women (38%) and 9 men (45%)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRelationship duration:\u003c\/strong\u003e Median of 9 months (interquartile range 3 to 12 months)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSexual practices:\u003c\/strong\u003e All couples reported unprotected vaginal sex in the month prior to recruitment; 7 couples (35%) also reported unprotected anal sex during that period\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHistory of BV:\u003c\/strong\u003e Reported by 17 women (81%)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHormonal contraception:\u003c\/strong\u003e Used by 11 women (52%)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eVaginal douching:\u003c\/strong\u003e Performed by 2 women (10%)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCircumcision:\u003c\/strong\u003e 4 men (19%) were circumcised\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eAll women had at least 3 Amsel criteria and a Nugent score of 4 to 10 at baseline; 19 women (90%) had a Nugent score of 7 to 10, indicating severe BV. One couple tested positive for chlamydia and was prescribed azithromycin (a single 1 g oral dose). One woman tested positive for gonorrhoea, and she and her male partner were prescribed azithromycin (single 1 g oral dose) and ceftriaxone (500 mg intramuscular injection).\u003c\/p\u003e\n\n\u003ch2 id=\"acceptability\"\u003eKey Findings: Was the Treatment Acceptable and Well-Tolerated?\u003c\/h2\u003e\n\n\u003cp\u003eThe primary goal of this pilot study was to assess whether male partners would find the combined oral and topical treatment acceptable and tolerable. The answer, based on the results, was a clear yes.\u003c\/p\u003e\n\n\u003cp\u003eOf the 16 couples who provided adherence and tolerability data:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e14 women received oral metronidazole and 2 women requested vaginal clindamycin\u003c\/li\u003e\n  \u003cli\u003eAll men received both oral metronidazole and topical clindamycin\u003c\/li\u003e\n  \u003cli\u003eFor 15 of the 16 couples, the male and female partner started treatment within 4 days of each other (10 couples started simultaneously)\u003c\/li\u003e\n  \u003cli\u003eFor 1 couple, the male partner started treatment one week after the female\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eAdherence to medication was high.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e13 women (93%) and 14 men (88%) took over 90% of their prescribed metronidazole tablets\u003c\/li\u003e\n  \u003cli\u003e11 men (69%) applied over 90% of their clindamycin doses\u003c\/li\u003e\n  \u003cli\u003eOf the two women who received vaginal clindamycin, one applied all doses and the other missed just one application\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eSide effects were relatively mild and uncommon.\u003c\/strong\u003e The most commonly reported adverse effects were:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eNausea and metallic taste in women (n = 3, 19%)\u003c\/li\u003e\n  \u003cli\u003eHeadaches in both men and women (n = 2, 12.5% each)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eOne man experienced a mild body rash involving his trunk and limbs (but notably \u003cem\u003enot\u003c\/em\u003e his penis) on day six of treatment and was advised not to take the final day of study medication. The women who received clindamycin reported no adverse effects at all.\u003c\/p\u003e\n\n\u003ch3\u003eBehavioural Practices During the Study\u003c\/h3\u003e\n\n\u003cp\u003eDuring the treatment period (days 0 to 7), 6 of 16 couples reported unprotected vaginal sex, 1 couple reported unprotected anal sex, and 5 couples reported oral sex. Between day 8 and day 28, all 16 couples reported unprotected vaginal sex, with 1 couple reporting unprotected anal sex during this time. One man ceased smoking and one man commenced smoking during the treatment period. One woman reported using condoms more frequently at day 28, and one woman reported a change from monthly to daily douching.\u003c\/p\u003e\n\n\u003ch2 id=\"microbiota\"\u003eKey Findings: Changes in the Genital Microbiota of Couples\u003c\/h2\u003e\n\n\u003cp\u003eThe secondary objective of the study was to investigate the impact of dual-partner treatment on the genital microbiota of couples. Researchers analysed the bacterial communities in vaginal swabs and penile skin swabs at baseline (day 0), day 8, and day 28.\u003c\/p\u003e\n\n\u003ch3\u003eBaseline Microbiota\u003c\/h3\u003e\n\n\u003cp\u003eOf the 21 couples who provided baseline data, 20 vaginal and 21 penile skin baseline specimens were available for analysis. At baseline, BV-associated bacteria — specifically \u003cem\u003eGardnerella\u003c\/em\u003e, \u003cem\u003ePrevotella\u003c\/em\u003e, and \u003cem\u003eSneathia\u003c\/em\u003e — were highly prevalent and abundant in vaginal specimens. Two women had a high abundance of \u003cem\u003eLactobacillus iners\u003c\/em\u003e, one of the \u003cem\u003eLactobacillus\u003c\/em\u003e species that can be present even in BV. In the penile skin specimens, \u003cem\u003eCorynebacterium\u003c\/em\u003e and BV-associated bacteria (specifically \u003cem\u003eFinegoldia\u003c\/em\u003e and \u003cem\u003ePeptoniphilus\u003c\/em\u003e) were highly prevalent and abundant.\u003c\/p\u003e\n\n\u003ch3\u003eImmediate and Sustained Effects on the Vaginal Microbiota\u003c\/h3\u003e\n\n\u003cp\u003eThe dual-partner treatment had an immediate and sustained effect on the composition of the vaginal microbiota. The median Bray-Curtis score comparing day 0 to day 8 was 0.03 (interquartile range 0 to 0.15), indicating a substantial change in the bacterial community immediately after treatment. This change was sustained — the median Bray-Curtis score comparing day 0 to day 28 was 0.03 (interquartile range 0.02 to 0.11), showing that the vaginal microbiota remained markedly different from baseline at the end of the 4-week follow-up period.\u003c\/p\u003e\n\n\u003cp\u003eThe researchers also observed:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eA reduction in the bacterial diversity of the vaginal microbiota (as measured by the Shannon Diversity Index), meaning the community became less diverse and more dominated by beneficial bacteria\u003c\/li\u003e\n  \u003cli\u003eA decrease in both the prevalence (how common a bacterium is across the group) and the abundance (how much of a bacterium is present in each sample) of BV-associated bacteria following treatment\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eEffects on the Penile Microbiota\u003c\/h3\u003e\n\n\u003cp\u003eTreatment also had an immediate effect on the composition of the cutaneous (skin) penile microbiota. The median Bray-Curtis score comparing day 0 to day 8 was 0.09 (interquartile range 0.04 to 0.17), demonstrating a notable shift in the penile bacterial community immediately following treatment. However, this effect was not as pronounced at day 28, with a median Bray-Curtis score of 0.38 (interquartile range 0.11 to 0.59) — indicating that the penile bacterial community was beginning to return toward its baseline composition.\u003c\/p\u003e\n\n\u003cp\u003eA decrease in the prevalence and abundance of BV-associated bacteria in the penile skin microbiota was observed immediately following treatment at day 8. However, the fact that the penile microbiota had drifted back toward baseline by day 28 suggests that the effect of the one-week topical and oral antibiotic course on penile bacteria may be temporary, potentially because the skin is continually exposed to the environment and recolonises over time.\u003c\/p\u003e\n\n\u003ch2 id=\"clinical-implications\"\u003eClinical Implications: What This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThese findings are encouraging for several important reasons.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFirst, the treatment is feasible.\u003c\/strong\u003e The high adherence rates — with 93% of women and 88% of men taking more than 90% of their metronidazole tablets, and 69% of men applying more than 90% of their clindamycin doses — demonstrate that men are willing to participate in treatment and can follow a twice-daily regimen involving both oral tablets and topical cream. This is critical information, as some previous partner-treatment studies may have failed in part because of poor adherence or acceptability.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSecond, the treatment is safe and well-tolerated.\u003c\/strong\u003e Side effects were generally mild (nausea, metallic taste, headache) and uncommon, affecting fewer than 1 in 5 participants. Even the topical clindamycin cream applied to the penis — a novel approach not previously studied — was well tolerated, with only one man experiencing a mild rash that did not involve the penis itself.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eThird, the treatment works at the microbiological level.\u003c\/strong\u003e Combined treatment changed the vaginal microbiota in a beneficial way — reducing bacterial diversity and decreasing the prevalence and abundance of BV-associated bacteria — and these changes persisted at least through day 28. In the penile microbiota, the immediate reduction in BV-associated bacteria at day 8 is particularly important because it supports the hypothesis that the male genital tract serves as a reservoir for these bacteria and that treating the male partner could reduce the risk of re-infection in women.\u003c\/p\u003e\n\n\u003cp\u003eThe fact that penile bacteria began to return toward baseline by day 28 raises an important question: does the male partner need to be re-treated, or does longer or repeated treatment provide more durable clearance? This is a question that only larger, longer-term studies can answer.\u003c\/p\u003e\n\n\u003cp\u003eIt is also worth noting that despite the treatment and the significant changes in vaginal microbiota, all 16 couples reported having unprotected vaginal sex between day 8 and day 28. This means the sustained improvement in the vaginal microbiota occurred \u003cem\u003edespite\u003c\/em\u003e ongoing unprotected sexual activity, which is a very encouraging sign. However, it also means that couples were continuing to exchange genital bacteria during the follow-up period, which may have contributed to the partial rebound of BV-associated bacteria on penile skin.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eStudy Limitations: What This Research Could Not Prove\u003c\/h2\u003e\n\n\u003cp\u003eAs a pilot study, this research has several important limitations that must be clearly understood.\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSmall sample size:\u003c\/strong\u003e Only 22 couples were recruited, and just 16 couples (76%) completed all study procedures. This small number limits the statistical power and the generalisability of the findings.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNo control group:\u003c\/strong\u003e This was an uncontrolled, non-randomised study. There was no comparison group of couples where only the woman was treated, so the researchers could not determine whether treating the male partner added any benefit beyond standard treatment alone.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eShort follow-up:\u003c\/strong\u003e The study only followed couples for 28 days. Given that BV recurrence typically occurs within 6 to 12 months, this study cannot answer whether the dual-partner approach actually reduces recurrence in the long term.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNot designed to measure recurrence:\u003c\/strong\u003e Although the researchers did record whether BV recurred within the 28-day follow-up, the study was not statistically powered to detect a difference in recurrence rates.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUrine specimens insufficient:\u003c\/strong\u003e Thirteen urine specimens failed to produce an adequate number of sequencing reads, meaning the researchers could not analyse the impact of treatment on the urethral microbiota of men — a key site for BV-associated bacteria.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSelf-reported adherence:\u003c\/strong\u003e Adherence to medication was based on participants' own reports, which can be subject to social desirability bias (participants reporting what they think the researchers want to hear).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSingle-centre study:\u003c\/strong\u003e All participants were recruited from one sexual health clinic in Melbourne, Australia, which may not represent the broader population of women with BV.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients\u003c\/h2\u003e\n\n\u003cp\u003eBased on this research, here is what women and their partners should know:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBV is a recurring condition — you are not alone.\u003c\/strong\u003e More than 50% of women experience a recurrence within 6 to 12 months of standard treatment. If your BV keeps coming back, it is worth discussing this with your healthcare provider.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eYour partner may play a role.\u003c\/strong\u003e Growing evidence suggests that BV-associated bacteria can be carried by male partners on penile skin and in the urethra, and that sexual activity can introduce these bacteria back into the vagina. If you have a regular male partner, it may be worth discussing whether partner treatment could be appropriate for you.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCombined oral and topical treatment for male partners is feasible.\u003c\/strong\u003e This study shows that men can and will complete a 7-day course of twice-daily oral antibiotics and topical cream applied to the penis. The treatment is generally well-tolerated, with only mild side effects such as nausea, headache, or metallic taste.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk your doctor about clinical trials.\u003c\/strong\u003e Larger clinical trials are needed to confirm whether dual-partner treatment actually reduces BV recurrence over 6 to 12 months. If you or your partner are interested in participating in research, ask your healthcare provider whether any relevant trials are available in your area.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCondoms may help.\u003c\/strong\u003e The evidence linking unprotected sex with BV acquisition and recurrence is strong. Using condoms consistently may reduce the exchange of BV-associated bacteria between partners.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eComplete your full course of antibiotics.\u003c\/strong\u003e The high adherence rates in this study (over 90% of doses taken) may be part of the reason the treatment was effective. Always finish the entire course of antibiotics as prescribed, even if your symptoms improve.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eIt is important to emphasise that this is a pilot study, and the dual-partner treatment approach is not currently a standard recommendation for routine clinical practice. The findings should not be interpreted as a directive to seek out antibiotics for male partners — the decision to treat a male partner should always be made in consultation with a healthcare provider, taking into account the potential benefits, risks, and the results of future larger studies.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is bacterial vaginosis and why does it keep coming back after treatment?\u003c\/h3\u003e\n\u003cp\u003eBacterial vaginosis (BV) happens when healthy Lactobacillus bacteria decrease and harmful anaerobic bacteria increase. Standard antibiotics often work at first, but more than half of women have a repeat episode within 6 to 12 months. Possible reasons include re-infection from a male partner, bacteria surviving inside the woman, or beneficial bacteria failing to return.\u003c\/p\u003e\n\u003ch3\u003eCan my male partner give me bacterial vaginosis again?\u003c\/h3\u003e\n\u003cp\u003eThere is strong evidence linking sexual activity with BV. Male partners can carry BV-associated bacteria on penile skin and in the urethra. Uncircumcised men may carry more bacteria under the foreskin. These bacteria could be passed back to a woman after her treatment, helping explain why BV often recurs.\u003c\/p\u003e\n\u003ch3\u003eWhat treatment did couples receive in this pilot study?\u003c\/h3\u003e\n\u003cp\u003eEach woman took oral metronidazole twice daily for 7 days, or used vaginal clindamycin cream if needed. Each male partner took oral metronidazole twice daily and applied clindamycin cream to the head of his penis (under the foreskin if uncircumcised) twice daily for 7 days. They were asked to avoid unprotected sex during treatment.\u003c\/p\u003e\n\u003ch3\u003eDid people find the partner treatment acceptable and were there side effects?\u003c\/h3\u003e\n\u003cp\u003eYes. In the 16 couples who completed the study, 93% of women and 88% of men took over 90% of their metronidazole tablets, and 69% of men applied over 90% of clindamycin doses. Side effects were mild and uncommon, including nausea, metallic taste, and headache. One man had a mild body rash.\u003c\/p\u003e\n\u003ch3\u003eDid the dual treatment actually change the genital bacteria?\u003c\/h3\u003e\n\u003cp\u003eYes. After treatment, women's vaginal bacteria showed a substantial and lasting change at day 28, with lower diversity and fewer BV-associated bacteria. Men's penile skin bacteria also showed an immediate decrease in BV-associated bacteria at day 8, but this effect was less clear by day 28.\u003c\/p\u003e\n\u003ch3\u003eWhat are the limitations of this pilot study?\u003c\/h3\u003e\n\u003cp\u003eThis was a small, uncontrolled study with only 22 couples, and just 16 completed all procedures. There was no comparison group, follow-up was only 28 days, and it was not designed to measure recurrence. Urine samples from men were insufficient to analyze urethral bacteria. Findings may not apply to everyone.\u003c\/p\u003e\n\u003ch3\u003eShould I ask my doctor to treat my male partner for bacterial vaginosis?\u003c\/h3\u003e\n\u003cp\u003eNot on your own. This dual-partner treatment is not yet a standard recommendation. If BV keeps returning, discuss it with your healthcare provider, who can consider whether partner treatment might be appropriate. Larger trials are needed to confirm if this approach reduces recurrence over 6 to 12 months.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e Combined oral and topical antimicrobial\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Erica L. Plummer, Lenka A. Vodstrcil, Jennifer A. Danielewski, Gerald L. Murray, Christopher K. Fairley, Suzanne M. Garland, Jane S. Hocking, Sepehr N. Tabrizi, Catriona S. Bradshaw\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e PLOS ONE, published January 2, 2018\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e 10.1371\/journal.pone.0190199\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFunding:\u003c\/strong\u003e The research was funded by a Near Miss Grant awarded to A\/Prof Catriona Bradshaw by the Central Clinical School, Monash University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eEthics approval:\u003c\/strong\u003e This trial received ethics approval from the Human Research and Ethics Committee of the Alfred Hospital, Melbourne, Australia (Project number 264\/15). Written informed consent was obtained from all participants. The study was prospectively filed with Australia's Therapeutics Goods Administration via the Clinical Trial Notification scheme (CT-2015-CTN-00884-1) and retrospectively registered with the Australian New Zealand Clinical Trials Registry (ACTRN12617001302347).\u003c\/p\u003e\n\n\u003cp\u003e\u003cem\u003eThis patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and does not constitute medical advice. Always consult a qualified healthcare professional regarding any medical condition or treatment decisions.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47405674201244,"sku":null,"price":0.0,"currency_code":"EUR","in_stock":true}],"url":"https:\/\/diagnosticdetectives.de\/products\/treating-male-partners-of-women-with-bacterial-vaginosis-a-promising-new-dual-therapy-approach-explained","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}